JetBlue Airways (JBLU) is back in focus after Jim Cramer criticized its recent earnings and outlook, following a single ...

Sangamo Therapeutics is back in focus as the latest price target reset gives investors fresh clues about how the story around this gene therapy name is evolving. With the prior target now withdrawn ...

Key Insights Significant control over FinWise Bancorp by individual investors implies that the general public has ...

After President Trump scrapped planned tariffs on European allies, easing worries about a transatlantic trade clash, ...

Why RAPT Therapeutics is Back on Investors’ Radar RAPT Therapeutics (RAPT) has drawn attention after a sharp move in its share price, with the stock showing strong gains over the past year and ...

Why recent management commentary matters for Molina Healthcare (MOH) Recent commentary from Molina Healthcare (MOH) ...

Granules India Ltd (BOM:532482) reports a robust 22% revenue increase, regulatory milestones, and strategic focus on ...

What Brookfield’s recent share performance tells you Brookfield (TSX:BN) has seen mixed returns recently, with a small gain ...

Our fair value estimate is 31% higher than Amdocs' analyst price target of US$103 Today we'll do a simple run through of a ...

The proposed "GBNB" trust would offer investors exposure to the native token of the BNB chain without having to directly own ...

Hudbay Minerals just received a fresh price target update, and that shift is reshaping how the stock’s story is being talked about right now. This change in target reflects a reassessment of what ...

The recent update to the price target for Commerce.com has put fresh attention on how investors are rethinking the story ...